


# Rev-CI™ (Reverse Cell Isolation) enabling FISH studies

- Performing FISH studies on samples composed of less than 5% cells of interest elevates the risk of a “false negative” result.
- Half of Lymphoma and Multiple Myeloma cases present with less than 5% B-lymphocytes or plasma cells respectively.
- This leads to an elevated risk of false negative FISH results for 50% of patients.



**1 in 2**

Patients at risk of false negative FISH Results without Rev-CI

## Clinical Consequences of False Negative/Inconclusive FISH Results



Inconclusive sub-classification of B-Cell lymphomas resulting in less targeted treatment



Inconclusive prognosis for Multiple Myeloma limits understanding of disease progression





Clinical decision-making with limited information leads to poor outcomes

## Rev-CI™ Solution: 98% Conclusive FISH Results

- Proprietary procedure that selectively enriches the sample for the cells of interest.
- REV-CI guarantees conclusive FISH results for up to 98% of samples, allowing for sub-classification of B-Cell lymphomas and definitive prognosis of Multiple Myelomas.

## Rev-CI™ INDUSTRY STANDARD



■ Conclusive FISH Results

■ Inconclusive/False Negative FISH Results

## REV-CI™ Proprietary Process for FISH Studies

	INDUSTRY STANDARD	PRECIPIO
1. Low Cellularity Sample Received	✓	✓
2. Cells of Interest Selectively Enriched Using Magnetic Beads	✗	✓
3. <b>Proprietary Rev-CI Process</b> Removes Magnetic Beads Allowing FISH Studies	✗	✓
4. FISH Studies Conducted	✓	✓
5. Results	Inconclusive FISH Results Due to Low Cellularity	Conclusive FISH Results